Regional therapeutic strategies in melanoma: Not just local disease control, but an opportunity to develop novel therapeutic strategies with potential implications for systemic therapy

Annals of Surgical Oncology

Volumn 15, Issue 11, 2008, Pages 2987-2990

  Tyler, Douglas ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUTHATHIONE SULFOXIMINE; CARBOPLATIN; DACARBAZINE; DACTINOMYCIN; EXHERIN; MELPHALAN; NERVE CELL ADHESION MOLECULE; PACLITAXEL; SORAFENIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VASOPRESSIN ANTAGONIST;

CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; DISEASE CONTROL; DRUG DOSE ESCALATION; EDITORIAL; ERYTHROCYTE CONCENTRATE; FOLLOW UP; HUMAN; MELANOMA; NONHUMAN; OPERATING ROOM; OXYGENATION; SURGICAL TECHNIQUE; SYSTEMIC THERAPY; TEMPERATURE; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 55149087702     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-008-0111-z     Document Type: Editorial

References (18)

1. DG Creech ET Kremetz RF Ryan 1958 Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit Ann Surg 184 616 32
2. Kroon HM, Moncrieff M, Kam PC, et al. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 2008; (in press)
3. MS Brady K Brown A Patel 2006 A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity Ann Surg Oncol 13 1123 9
4. GM Beasley RP Petersen J Yoo 2008 Isolated limb infusion for in-transit malignant melanoma of the extremity: a well tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 15 2195 2205
5. Beasley GM, Petersen RP, McMahon NS, et al. A Multi-institutional experience of isolated limb infusion: defining response and toxicity in the United States. Submitted to the Southern Surgical Association meeting 2008
6. WR Cornett LM McCall RP Petersen 2006 Prospective randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone versus melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020 J Clin Oncol 24 4196 201
7. CK Augustine Y Yoshimoto M Gupta 2008 Inhibition of N-cadherin significantly enhances anti-tumor activity of cytotoxic therapies in regional and systemic melanoma treatment Cancer Res 68 3777 84
8. Beasley G, McMahon N, Sanders G, et al. A phase I/II study of systemic ADH-1 in combination with isolated limb infusion with melphalan (ILI-M) in patients (pts) with locally advanced in-transit melanoma. Proc Am Soc Clin Oncol 2008; 26:486. Abstract number 9013
9. J Green D Vistica R Young 1984 Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion Cancer Res 44 5427 31
10. K Suzukake B Vistica D Vistica 1983 Resistant tumor cells and its relationship to intracellular glutathione content Biochem Pharmacol 32 165 7
11. E Grubbs T Ueno O Abdel-Wahab 2004 Modulation of resistance to regional chemotherapy in the extremity melanoma model Surgery 136 210 8
12. H Davies GR Bignell C Cox 2002 Mutations of the BRAF gene in human cancer Nature 417 949 54
13. DF McDermott JA Sosman R Gonzalez 2008 Double-blind randomized phase II study of the combination of Sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group J Clin Oncol 26 2178 85
14. KT Flaherty J Schiller LM Schuchter 2008 A phase I trial of the oral multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel Clin Cancer Res 14 4836 4842
15. T Eisen T Ahmad KT Flaherty 2006 Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis Br J Cancer 95 581 6
16. T Ueno SH Ko E Grubbs 2006 Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine Mol Cancer Ther 5 732 8
17. SH Ko T Ueno Y Yoshimoto 2006 Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity Clin Cancer Res 12 289 97
18. Y Yoshimoto CK Augustine JS Yoo 2007 Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents Mol Cancer Ther 6 1492 500